You are here: Industry Insights > Market News

News List

Many With Mental Illness Miss Out on HIV Tests drugs.com
January 20, 2017
People with severe mental illness are only slightly more likely to be screened for HIV than those in the general population, a new study finds.
Opdivo demonstrated efficacy and improved survival in patients with previously treated advanced gast cphi-online
January 20, 2017
Opdivo demonstrated a 37% reduction in the risk of death compared to placebo.
Allergan's Rhofade cream, 1% for persistent facial erythema cphi-online
January 20, 2017
Once-daily treatment reduces persistent facial erythema associated with rosacea through 12 hours.
CFDA Chemical Drug Process Change Issue in the New Regulation Arousing Heated Discussion en-cphi
January 19, 2017
It gradually approaches the Chinese New Year holidays, but CFDA has never stopped its pace of intending to rectify the industry and continuing to introduce new policies.
8 Protected TCM Varieties Exceeding “RMB 1 Billion”, Which Do You Think is the Next One? en-cphi
January 19, 2017
There were 21 protected TCM varieties whose sales exceeding RMB 500 million in 2015, of which, the sales of 8 varieties exceed RMB 1 billion.
Eisai acquires manufacturing rights for API from Roche to treat insomnia pharmaceutical-technology
January 19, 2017
Eisai has acquired the rights for manufacturing active pharmaceutical ingredients (API) for Japan from F Hoffman-La Roche for the insomnia treatment / anaesthesia induction agent flunitrazepam.
Malecare launches new mobile application Cancergraph to track cancer symptoms pharmaceutical-technology
January 19, 2017
US-based men’s cancer survivor support and advocacy national non-profit organisation Malecare has launched a new mobile application, Cancergraph, which tracks cancer symptoms.
Cancer Research UK, CRT and MRC to target cancer immunotherapies pharmaceutical-technology
January 19, 2017
Cancer Research UK, Cancer Research Technology (CRT) and MRC Technology are set to collaborate in a bid to focus on cancer immunotherapies.
Senhwa Biosciences CX-4945 granted Orphan Drug Designation by the US FDA in Cholangiocarcinoma pharmaasia
January 19, 2017
CX-4945 has demonstrated favorable safety, pharmacokinetic and pharmacodynamic characteristics in the treatment of advanced Cholangiocarcinoma.
Sun Pharma announces positive topline results of Phase-3 clinical trial for Seciera pharmaasia
January 19, 2017
Seciera meets primary and key secondary endpoints in pivotal trial, and shows efficacy at 12 weeks of treatment.